American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

by admin June 29, 2024
June 29, 2024
Biden administration to lower costs for 64 drugs through inflation penalties on drugmakers

The Biden administration on Wednesday said it will impose inflation penalties on 64 prescription drugs for the third quarter of this year, lowering costs for certain older Americans enrolled in Medicare. 

President Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for 2024. A provision of Biden’s Inflation Reduction Act requires drugmakers to pay rebates to Medicare, the federal health program for Americans over age 65, if they hike the price of a medication faster than the rate of inflation. 

It is separate from another provision under the law that allows Medicare to negotiate lower prescription drug prices with manufacturers. On average, Americans pay two to three times more than patients in other developed nations for prescription drugs, according to the Biden administration.

Some patients will pay a lower coinsurance rate for the 64 drugs covered under Wednesday’s announcement, which fall under Medicare Part B, for the period from July 1 to Sept. 30 “since each drug company raised prices faster than the rate of inflation,” according to a release from the administration.

Some Medicare Part B patients may save as much as $4,593 per day if they use those drugs during the quarter, the release added.  

More than 750,000 Medicare patients use the drugs each year, according to the release. The medications treat conditions such as cancer, certain infections and a bone disease called osteoporosis.

“Without the Inflation Reduction Act, seniors were completely exposed to Big Pharma’s price hikes. Not anymore,” Neera Tanden, White House domestic policy advisor, said in the release.

The Centers for Medicare & Medicaid Services plans to send the first invoices to drugmakers in 2025 for the rebates owed to the program.

In December, Biden released a list of 48 prescription drugs that would be subject to inflation penalties during the first quarter of 2024.

This post appeared first on NBC NEWS

0
FacebookTwitterGoogle +Pinterest
previous post
Axios omits crucial details about economists who say Trump will destroy the economy
next post
NFL hit with $4.8 billion in damages over ‘Sunday Ticket’ antitrust case

Related Posts

Barclays profit surges 23% in Q3, beating forecasts:...

October 24, 2024

Getty Images stock price has crashed: will it...

March 16, 2025

US spot Ethereum ETFs see highest daily inflows;...

November 30, 2024

Pharma giant Roche pledges $50 billion US investment...

April 22, 2025

Rolls-Royce share price hits turbulence: can it still...

March 31, 2025

Dow, S&P 500 slip as investors assess hot...

December 13, 2024

How America Inc is boosting security spending after...

April 28, 2025

Zara’s owner Inditex shows resilience despite unexpected Q3...

December 11, 2024

Long IONS: Ionis Pharmaceuticals, Double Bottom Sets Stage...

January 14, 2025

Google loses antitrust case over search

August 7, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Why Asia is quietly turning its back on US dollar

      May 11, 2025
    • President Trump floats 80% tariff on Chinese goods ahead of key trade talks

      May 11, 2025
    • UK’s Crown Estate clears offshore wind expansion to raise energy output

      May 11, 2025
    • What extended conflict between India and Pakistan could cost their economies

      May 11, 2025
    • CoreWeave eyes $1.5B bond raise to ease debt load following lacklustre IPO: report

      May 10, 2025

    Categories

    • Business (2,842)
    • Investing (2,380)
    • Latest News (1,984)
    • Politics (1,530)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved